Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin C Michel

Showing results (1-10 of 341) with videos related to

Pageof 35
Sort By:
Clinical Drug Investigation|July 2, 2016
Impact of Formulation on the Pharmacokinetic Profile of DutasterideMartin C Michel
The Journal of Urology|May 22, 2020
Editorial CommentMartin C Michel
Idrugs : the Investigational Drugs Journal|December 23, 2003
Lower urinary tract disorders - Ray Fuller Symposium. Physiology, pharmacology and therapeutics approachesMartin C Michel
Neurourology and Urodynamics|November 2, 2022
Are β<sub>3</sub> -adrenoceptor gene polymorphisms relevant for urology?Martin C Michel
Expert Opinion on Pharmacotherapy|June 24, 2008
Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndromeMartin C Michel
British Journal of Clinical Pharmacology|May 14, 2011
Clinical pharmacology of functional disorders of the urogenital systemMartin C Michel
Frontiers in Pharmacology|August 4, 2011
Challenges in the pharmacotherapy of urogenital disordersMartin C Michel
Urology|November 8, 2011
Editorial commentMartin C Michel
International Journal of Urology : Official Journal of the Japanese Urological Association|February 10, 2020
Where will the next generation of medical treatments for overactive bladder syndrome come from?Martin C Michel
The Journal of Urology|January 25, 2021
Editorial CommentMartin C Michel
Pageof 35

Showing results (1-10 of 341) with videos related to

Sort By:
Pageof 35
Clinical Drug Investigation|July 2, 2016
Impact of Formulation on the Pharmacokinetic Profile of DutasterideMartin C Michel
The Journal of Urology|May 22, 2020
Editorial CommentMartin C Michel
Idrugs : the Investigational Drugs Journal|December 23, 2003
Lower urinary tract disorders - Ray Fuller Symposium. Physiology, pharmacology and therapeutics approachesMartin C Michel
Neurourology and Urodynamics|November 2, 2022
Are β<sub>3</sub> -adrenoceptor gene polymorphisms relevant for urology?Martin C Michel
Expert Opinion on Pharmacotherapy|June 24, 2008
Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndromeMartin C Michel
British Journal of Clinical Pharmacology|May 14, 2011
Clinical pharmacology of functional disorders of the urogenital systemMartin C Michel
Frontiers in Pharmacology|August 4, 2011
Challenges in the pharmacotherapy of urogenital disordersMartin C Michel
Urology|November 8, 2011
Editorial commentMartin C Michel
International Journal of Urology : Official Journal of the Japanese Urological Association|February 10, 2020
Where will the next generation of medical treatments for overactive bladder syndrome come from?Martin C Michel
The Journal of Urology|January 25, 2021
Editorial CommentMartin C Michel
Pageof 35